Anna Eduardovna Tsygankova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Anna Eduardovna Tsygankova has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Elena Vasilevna Volchkova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
7 shared publications - Andrey Nikolaevich Gerasimov
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical and Biological Agency
6 shared publications - Vladimir Petrovich Chulanov
Engelhardt Institute of Molecular Biology, Russian Academy of Science, Moscow 119991, Russia
6 shared publications - Valerii Anatolevich Malov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
3 shared publications - Anastasia A. Fomicheva
I.M. Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - Anton A. Privalenko
CentralResearch Institute of Epidemiology, Moscow, Russian Federation
2 shared publications
Latest Publications
- 13 January 2026
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 24 (4) , 270-282
Understanding the Burden of Coinfection: COVID-19 in Hospitalized Patients with Diagnosed and Undiagnosed Advanced HIV
Background:: In their struggle with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, physicians are intensively focused on high-risk patient groups. One such group includes immunosuppressed people living with HIV (PLWH). This study considers the most vulnerable cohort of advanced HIV patients in order to identify potential risk factors for unfavorable SARS-CoV-2 disease (COVID-19) outcomes. Method:: This study analyzed data from a census-based sample of 500 patients. The sample en-compassed all consecutive patients during the study period (2020–2022) who met the inclusion and exclusion criteria. All selected patients, aged over 18 years, were hospitalized with confirmed advanced HIV and moderate to severe COVID-19 coinfection at the Infectious Disease Hospital (IDH) in Moscow from 2020 to 2022. Results:: The overall mortality rate reached 27.0% (135 deaths; 95% CI 23.3–30.9%). Primary analysis identified three key independent predictors of mortality: mechanical ventilation demon-strated the strongest association (aOR 4.29, 95% CI 3.15–5.84, p < 0.001), followed by profound immunosuppression (CD4+ counts below 50 cells/mm³; aOR 3.28, 95% CI 2.41–4.47, p < 0.001) and high HIV viral load exceeding 20,000 copies/mL (aOR 3.37, 95% CI 2.52–4.51, p = 0.003). Secondary outcomes revealed important clinical patterns: oxygen support requirements showed a graded mortality risk from low-flow systems (aOR 3.40, p < 0.001) to mechanical ventilation (aOR 4.29, p < 0.001), while newly diagnosed HIV patients faced significantly higher mortality (46.2%) compared to known HIV cases (24.6%). Opportunistic infections substantially worsened prognosis, particularly Kaposi's sarcoma (aOR 3.17, 95% CI 2.28–4.41, p < 0.001), pneumocystis pneumonia (aOR 2.74, 95% CI 1.98–3.79, p < 0.001), and CMV pneumonitis (aOR 2.56, 95% CI 1.85–3.54, p < 0.001). Protective factors included preserved immunity (CD4+ >500 cells/mm³; aOR 2.77, 95% CI 2.08–3.69, p = 0.03) and virological suppression (aOR 2.22, 95% CI 1.67–2.95, p = 0.001). Ferritin levels above 600 ng/mL emerged as an additional risk marker (aOR 1.73, 95% CI 1.32–2.27, p = 0.0006), though with less robust association than primary predictors. Conclusion:: These findings can provide physicians with a risk-based prioritization algorithm for patients with COVID-19 and advanced HIV coinfection. Identifying patients at highest risk for unfavorable outcomes ensures timely ICU admission, faster patient examination, and initiation of dedicated treatment.
- 13 January 2026
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 24 (4) , 270-282
Understanding the Burden of Coinfection: COVID-19 in Hospitalized Patients with Diagnosed and Undiagnosed Advanced HIV
Background:: In their struggle with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, physicians are intensively focused on high-risk patient groups. One such group includes immunosuppressed people living with HIV (PLWH). This study considers the most vulnerable cohort of advanced HIV patients in order to identify potential risk factors for unfavorable SARS-CoV-2 disease (COVID-19) outcomes. Method:: This study analyzed data from a census-based sample of 500 patients. The sample en-compassed all consecutive patients during the study period (2020–2022) who met the inclusion and exclusion criteria. All selected patients, aged over 18 years, were hospitalized with confirmed advanced HIV and moderate to severe COVID-19 coinfection at the Infectious Disease Hospital (IDH) in Moscow from 2020 to 2022. Results:: The overall mortality rate reached 27.0% (135 deaths; 95% CI 23.3–30.9%). Primary analysis identified three key independent predictors of mortality: mechanical ventilation demon-strated the strongest association (aOR 4.29, 95% CI 3.15–5.84, p < 0.001), followed by profound immunosuppression (CD4+ counts below 50 cells/mm³; aOR 3.28, 95% CI 2.41–4.47, p < 0.001) and high HIV viral load exceeding 20,000 copies/mL (aOR 3.37, 95% CI 2.52–4.51, p = 0.003). Secondary outcomes revealed important clinical patterns: oxygen support requirements showed a graded mortality risk from low-flow systems (aOR 3.40, p < 0.001) to mechanical ventilation (aOR 4.29, p < 0.001), while newly diagnosed HIV patients faced significantly higher mortality (46.2%) compared to known HIV cases (24.6%). Opportunistic infections substantially worsened prognosis, particularly Kaposi's sarcoma (aOR 3.17, 95% CI 2.28–4.41, p < 0.001), pneumocystis pneumonia (aOR 2.74, 95% CI 1.98–3.79, p < 0.001), and CMV pneumonitis (aOR 2.56, 95% CI 1.85–3.54, p < 0.001). Protective factors included preserved immunity (CD4+ >500 cells/mm³; aOR 2.77, 95% CI 2.08–3.69, p = 0.03) and virological suppression (aOR 2.22, 95% CI 1.67–2.95, p = 0.001). Ferritin levels above 600 ng/mL emerged as an additional risk marker (aOR 1.73, 95% CI 1.32–2.27, p = 0.0006), though with less robust association than primary predictors. Conclusion:: These findings can provide physicians with a risk-based prioritization algorithm for patients with COVID-19 and advanced HIV coinfection. Identifying patients at highest risk for unfavorable outcomes ensures timely ICU admission, faster patient examination, and initiation of dedicated treatment.
- Open Access
- 14 December 2025
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 30 (3) , 180-193
Predictors of severe COVID-19: older age and comorbidity
BACKGROUND: Older age and comorbidity are recognized as significant risk factors for severe COVID-19. However, the combined impact of these factors on disease outcomes, especially in different age groups, remains unclear. This study focuses on older patients with chronic comorbidities in order to address this gap. AIM: This study aimed to evaluate the role of older age and comorbidities in prediction of severe COVID-19 and mortality in hospitalized patients. METHODS: This cross-sectional, retrospective study included 604 patients aged 18–99 years who were treated at Infectious Diseases Clinical Hospital No. 2 of the Moscow Healthcare Department for laboratory-confirmed (ICD-10 code: U07.1) COVID-19 between September 2020 and November 2022. Demographic characteristics, comorbidities, clinical outcomes (recovery, improvement, and mortality rates), and COVID-19 severity were evaluated. RESULTS: An analysis of 604 hospitalized patients revealed an increase in mortality rates with age: 4.1% in patients under 60 years old, 12.7% in patients aged 60–74 years, 16.4% in patients aged 75–89 years, and 21.9% in patients aged 90 years and older. The most common comorbidity-associated risk factors included chronic kidney disease (mortality rate: 23.2%), myocardial ischemia (19.7%), and type 2 diabetes mellitus (18%). The infection was atypical, without fever in 21% of patients, primarily those in the older age group. Stratified analysis showed that the role of specific risk factors, such as chemotherapy, myocardial ischemia, and chronic kidney disease, varied across age groups. CONCLUSION: Older age and comorbidities are independent risk factors for severe COVID-19 and fatal outcomes. Patients over the age of 75 years with chronic diseases require special attention. Early diagnosis and personalized management strategies may improve outcomes in this age group.
- 14 December 2025
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 30 (3) , 180-193
Open AccessPredictors of severe COVID-19: older age and comorbidity
BACKGROUND: Older age and comorbidity are recognized as significant risk factors for severe COVID-19. However, the combined impact of these factors on disease outcomes, especially in different age groups, remains unclear. This study focuses on older patients with chronic comorbidities in order to address this gap. AIM: This study aimed to evaluate the role of older age and comorbidities in prediction of severe COVID-19 and mortality in hospitalized patients. METHODS: This cross-sectional, retrospective study included 604 patients aged 18–99 years who were treated at Infectious Diseases Clinical Hospital No. 2 of the Moscow Healthcare Department for laboratory-confirmed (ICD-10 code: U07.1) COVID-19 between September 2020 and November 2022. Demographic characteristics, comorbidities, clinical outcomes (recovery, improvement, and mortality rates), and COVID-19 severity were evaluated. RESULTS: An analysis of 604 hospitalized patients revealed an increase in mortality rates with age: 4.1% in patients under 60 years old, 12.7% in patients aged 60–74 years, 16.4% in patients aged 75–89 years, and 21.9% in patients aged 90 years and older. The most common comorbidity-associated risk factors included chronic kidney disease (mortality rate: 23.2%), myocardial ischemia (19.7%), and type 2 diabetes mellitus (18%). The infection was atypical, without fever in 21% of patients, primarily those in the older age group. Stratified analysis showed that the role of specific risk factors, such as chemotherapy, myocardial ischemia, and chronic kidney disease, varied across age groups. CONCLUSION: Older age and comorbidities are independent risk factors for severe COVID-19 and fatal outcomes. Patients over the age of 75 years with chronic diseases require special attention. Early diagnosis and personalized management strategies may improve outcomes in this age group.
- Open Access
- 1 March 2024
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 29 (1) , 5-17
Predicting COVID-19 outcomes in patients at advanced stages of HIV infection: a model-based approach
BACKGROUND: Today, clinicians and their decisions extensively rely on specific treatment algorithms. These algorithms include prognostic models to identify high risk patients requiring hospital admission and clinical monitoring. This study suggests a prognostic model for forecasting COVID-19 outcomes in patients with advanced HIV infection, considering the high risk of unfavorable outcomes and the need for a specialized approach. AIM: To develop a prognostic model that combines predictors of unfavorable COVID-19 outcomes in patients with advanced HIV infection. MATERIALS AND METHODS: The study was based on 500 medical records of patients with advanced HIV infection admitted for confirmed COVID-19 between March 1, 2020, and December 31, 2022, and inpatient treatment at the Infectious Diseases Hospital in Moscow. RESULTS: All 500 patients were evaluated for 167 predictive markers for unfavorable COVID-19 outcomes, outlining 50 indicators that significantly varied across the subgroups of patients with both advanced HIV infection and COVID-19 depending on the presence of favorable or poor outcomes. Oxygen therapy was the most significant factor showing a strong correlation with poor outcomes in patients with advanced HIV infection and COVID-19. Subsequently, predictors were selected stepwise to enhance the predictive accuracy of the resulting model by adding more factors. The resulting model included seven factors: oxygen therapy requirements, CD4+ count under 50 cells/μL; manifested CMV infection with lung damage; elevated levels of lactate dehydrogenase, urea, and fibrinogen; and the presence of unspecified encephalitis. Using the available data in the calculations, a prognostic scenario and a receiver operating characteristic (ROC) curve were created to assess the practical significance of the proposed prognostic model. The area under the ROC curve was 90.9%, confirming the prediction accuracy and overall practical significance of the model. CONCLUSIONS: The proposed prognostic model enables the assessment of potential outcomes and planning of adequate therapies in patients with HIV and COVID-19 co-infection admitted to hospitals at advanced stages of the disease.
- 1 March 2024
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 29 (1) , 5-17
Open AccessPredicting COVID-19 outcomes in patients at advanced stages of HIV infection: a model-based approach
BACKGROUND: Today, clinicians and their decisions extensively rely on specific treatment algorithms. These algorithms include prognostic models to identify high risk patients requiring hospital admission and clinical monitoring. This study suggests a prognostic model for forecasting COVID-19 outcomes in patients with advanced HIV infection, considering the high risk of unfavorable outcomes and the need for a specialized approach. AIM: To develop a prognostic model that combines predictors of unfavorable COVID-19 outcomes in patients with advanced HIV infection. MATERIALS AND METHODS: The study was based on 500 medical records of patients with advanced HIV infection admitted for confirmed COVID-19 between March 1, 2020, and December 31, 2022, and inpatient treatment at the Infectious Diseases Hospital in Moscow. RESULTS: All 500 patients were evaluated for 167 predictive markers for unfavorable COVID-19 outcomes, outlining 50 indicators that significantly varied across the subgroups of patients with both advanced HIV infection and COVID-19 depending on the presence of favorable or poor outcomes. Oxygen therapy was the most significant factor showing a strong correlation with poor outcomes in patients with advanced HIV infection and COVID-19. Subsequently, predictors were selected stepwise to enhance the predictive accuracy of the resulting model by adding more factors. The resulting model included seven factors: oxygen therapy requirements, CD4+ count under 50 cells/μL; manifested CMV infection with lung damage; elevated levels of lactate dehydrogenase, urea, and fibrinogen; and the presence of unspecified encephalitis. Using the available data in the calculations, a prognostic scenario and a receiver operating characteristic (ROC) curve were created to assess the practical significance of the proposed prognostic model. The area under the ROC curve was 90.9%, confirming the prediction accuracy and overall practical significance of the model. CONCLUSIONS: The proposed prognostic model enables the assessment of potential outcomes and planning of adequate therapies in patients with HIV and COVID-19 co-infection admitted to hospitals at advanced stages of the disease.
- Open Access
- 1 March 2024
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 29 (1) , 64-73
Epidemiology, course and predictors of long-term COVID infection (long COVID): A review
The COVID-19 pandemic has posed a serious challenge to the healthcare system in the 21st century. At present, over 771 million cases have been reported worldwide. Apart from the acute symptoms, many patients experience long-term consequences of the infection, which greatly affect their quality of life. The collection of these long-term effects is called “long COVID.” Therefore, the consequences of COVID-19 must be studied to develop effective strategies for combating them. This review aimed to provide an overview of the history of long COVID and discuss the characteristics of contemporary terminology. This review also presents data on the prevalence of long COVID, primary symptoms, and risk factors and explores potential biomarkers, prognosis, and prospects for subsequent clinical trials.
- 1 March 2024
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 29 (1) , 64-73
Open AccessEpidemiology, course and predictors of long-term COVID infection (long COVID): A review
The COVID-19 pandemic has posed a serious challenge to the healthcare system in the 21st century. At present, over 771 million cases have been reported worldwide. Apart from the acute symptoms, many patients experience long-term consequences of the infection, which greatly affect their quality of life. The collection of these long-term effects is called “long COVID.” Therefore, the consequences of COVID-19 must be studied to develop effective strategies for combating them. This review aimed to provide an overview of the history of long COVID and discuss the characteristics of contemporary terminology. This review also presents data on the prevalence of long COVID, primary symptoms, and risk factors and explores potential biomarkers, prognosis, and prospects for subsequent clinical trials.
- Open Access
- 1 March 2024
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 29 (1) , 18-28
The effect of vaccination against the COVID-19 on the course and outcomes of a new coronavirus infection: a retrospective analysis of laboratory and clinical indicators of hospitalized patients
BACKGROUND: The Gam-COVID-Vac vaccine was proven effective in preventing the severe course and adverse outcomes of COVID-19 during different periods of the pandemic. However, the effect of vaccination on laboratory marker levels in hospitalized patients during the spread of the omicron variant of SARS-CoV-2 has not been sufficiently studied. AIM: To assess the effect of vaccination on the severity and outcomes of COVID-19 in hospitalized patients during the dominance of the SARS-CoV-2 omicron variant in Russia. MATERIALS AND METHODS: This case–control study included adult patients diagnosed with COVID-19 (U07.1) and hospitalized in infectious hospitals in Moscow between February 1, 2022, and July 31, 2022 (n=119). The main group included individuals vaccinated with two doses of Sputnik V vaccine (n=59). The control group included individuals who were not vaccinated (n=60). The median patient age was 66 [interquartile range, 41–66] years, and 58.8% were female. The chi-square test for categorical variables and the Mann–Whitney test for continuous variables were used for the analysis. P-values 0.05 were considered statistically significant. RESULTS: Viral pneumonia was less likely to develop in the vaccinated group than in the unvaccinated group (46.7% and 18.6%, respectively, p = 0.007). The proportion of patients without lung damage (0 CT-severity scores) in the vaccinated group (72.0%) was significantly higher than that in the unvaccinated group (42.9%) (p=0.003). In the vaccinated group, the levels of C-reactive protein on admission were lower (29.1 [7.4–68.6] mg/L and 75.1 [32.4–104.0] mg/L, p 0.001), and the highest level was recorded during hospitalization (38.2 [12.0–84.0] mg/L and 92.2 [45.3–137.4] mg/L, p 0.001). The D-dimer levels before discharge were lower in the group of patients vaccinated 6 months ago than in the unvaccinated group (157.0 [107.0–297.0] ng/mL and 316.0 [125.0–556.0] ng/mL, respectively, p = 0.014). The frequency of deaths in the control group (11.7%) was 6.9 times higher than that in the main group (1.7%) (p = 0.030). CONCLUSIONS: Completion of the primary vaccination course of Sputnik V vaccine resulted in lower levels of prognostic markers of severe COVID-19 (C-reactive protein and D-dimer) and a decrease in the frequency of pulmonary and fatal outcomes than in the unvaccinated group during the dominance of the omicron variant of SARS-CoV-2.
- 1 March 2024
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 29 (1) , 18-28
Open AccessThe effect of vaccination against the COVID-19 on the course and outcomes of a new coronavirus infection: a retrospective analysis of laboratory and clinical indicators of hospitalized patients
BACKGROUND: The Gam-COVID-Vac vaccine was proven effective in preventing the severe course and adverse outcomes of COVID-19 during different periods of the pandemic. However, the effect of vaccination on laboratory marker levels in hospitalized patients during the spread of the omicron variant of SARS-CoV-2 has not been sufficiently studied. AIM: To assess the effect of vaccination on the severity and outcomes of COVID-19 in hospitalized patients during the dominance of the SARS-CoV-2 omicron variant in Russia. MATERIALS AND METHODS: This case–control study included adult patients diagnosed with COVID-19 (U07.1) and hospitalized in infectious hospitals in Moscow between February 1, 2022, and July 31, 2022 (n=119). The main group included individuals vaccinated with two doses of Sputnik V vaccine (n=59). The control group included individuals who were not vaccinated (n=60). The median patient age was 66 [interquartile range, 41–66] years, and 58.8% were female. The chi-square test for categorical variables and the Mann–Whitney test for continuous variables were used for the analysis. P-values 0.05 were considered statistically significant. RESULTS: Viral pneumonia was less likely to develop in the vaccinated group than in the unvaccinated group (46.7% and 18.6%, respectively, p = 0.007). The proportion of patients without lung damage (0 CT-severity scores) in the vaccinated group (72.0%) was significantly higher than that in the unvaccinated group (42.9%) (p=0.003). In the vaccinated group, the levels of C-reactive protein on admission were lower (29.1 [7.4–68.6] mg/L and 75.1 [32.4–104.0] mg/L, p 0.001), and the highest level was recorded during hospitalization (38.2 [12.0–84.0] mg/L and 92.2 [45.3–137.4] mg/L, p 0.001). The D-dimer levels before discharge were lower in the group of patients vaccinated 6 months ago than in the unvaccinated group (157.0 [107.0–297.0] ng/mL and 316.0 [125.0–556.0] ng/mL, respectively, p = 0.014). The frequency of deaths in the control group (11.7%) was 6.9 times higher than that in the main group (1.7%) (p = 0.030). CONCLUSIONS: Completion of the primary vaccination course of Sputnik V vaccine resulted in lower levels of prognostic markers of severe COVID-19 (C-reactive protein and D-dimer) and a decrease in the frequency of pulmonary and fatal outcomes than in the unvaccinated group during the dominance of the omicron variant of SARS-CoV-2.
- Open Access
- 11 December 2023
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 18 (5)
Previously Diagnosed HIV Infection in Patients with COVID-19 and Advanced HIV Disease Improves Their Survival
Background: Currently, the global HIV epidemic remains ongoing, with a significant number of patients having undiagnosed advanced HIV disease. Providing medical care to patients with both COVID-19 and advanced HIV disease presents specific challenges due to the simultaneous lung damage caused by the SARS-CoV-2 virus and opportunistic pathogens. Objectives: This study aimed to explain the rationale behind recommending HIV screening for patients with severe COVID-19. Methods: A single-center retrospective cohort study was conducted using electronic medical records from a specialized hospital in Moscow that focused on coinfection with HIV/COVID-19. Among the 3,563 patients hospitalized in the relevant departments during the study period, 408 patients were included based on the inclusion/exclusion criteria. Out of the 408 patients with both COVID-19 and advanced HIV disease, 132 individuals were newly diagnosed with HIV infection, while 276 individuals had a previously established HIV diagnosis. Results: The mortality rate in the group of patients with COVID-19 and advanced HIV disease was 31.7% (95% CI, 27.3 - 36.3%). Among patients with COVID-19 and newly diagnosed advanced HIV disease, the mortality rate was 45.5% (95% CI, 37.1 - 54%), while in the group of patients with previously diagnosed advanced HIV disease, the mortality rate was 25% (95% CI, 20.2 - 30.4%). The proportion of individuals with critical CT-4 lung disease in the first group was 32.3% compared to 9.4% in the second group (P < 0.001). The median CD4+ count was 20 cells/µL in the first group compared with 88 cells/µL in the second group (P < 0.001). Conclusions: The presence of pneumocystis pneumonia increased the risk of death by 2.51 times in patients with COVID-19 and newly diagnosed advanced HIV disease. Additionally, Kaposi's sarcoma increased the risk of death by 1.31 times in the same patient group. Furthermore, the detection of HIV infection for the first time during hospitalization due to COVID-19 in the entire study cohort increased the risk of death by 2.21 times.
- 11 December 2023
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 18 (5)
Open AccessPreviously Diagnosed HIV Infection in Patients with COVID-19 and Advanced HIV Disease Improves Their Survival
Background: Currently, the global HIV epidemic remains ongoing, with a significant number of patients having undiagnosed advanced HIV disease. Providing medical care to patients with both COVID-19 and advanced HIV disease presents specific challenges due to the simultaneous lung damage caused by the SARS-CoV-2 virus and opportunistic pathogens. Objectives: This study aimed to explain the rationale behind recommending HIV screening for patients with severe COVID-19. Methods: A single-center retrospective cohort study was conducted using electronic medical records from a specialized hospital in Moscow that focused on coinfection with HIV/COVID-19. Among the 3,563 patients hospitalized in the relevant departments during the study period, 408 patients were included based on the inclusion/exclusion criteria. Out of the 408 patients with both COVID-19 and advanced HIV disease, 132 individuals were newly diagnosed with HIV infection, while 276 individuals had a previously established HIV diagnosis. Results: The mortality rate in the group of patients with COVID-19 and advanced HIV disease was 31.7% (95% CI, 27.3 - 36.3%). Among patients with COVID-19 and newly diagnosed advanced HIV disease, the mortality rate was 45.5% (95% CI, 37.1 - 54%), while in the group of patients with previously diagnosed advanced HIV disease, the mortality rate was 25% (95% CI, 20.2 - 30.4%). The proportion of individuals with critical CT-4 lung disease in the first group was 32.3% compared to 9.4% in the second group (P < 0.001). The median CD4+ count was 20 cells/µL in the first group compared with 88 cells/µL in the second group (P < 0.001). Conclusions: The presence of pneumocystis pneumonia increased the risk of death by 2.51 times in patients with COVID-19 and newly diagnosed advanced HIV disease. Additionally, Kaposi's sarcoma increased the risk of death by 1.31 times in the same patient group. Furthermore, the detection of HIV infection for the first time during hospitalization due to COVID-19 in the entire study cohort increased the risk of death by 2.21 times.
- Open Access
- 13 December 2022
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 27 (3) , 148-163
Predictive model of COVID-19 outcomes in patients with advanced HIV infection
BACKGROUND: No studies have examined the course and outcomes of coronavirus disease 2019 (COVID-19) in patients with advanced HIV infection, which prompted this analysis. AIM: To identify predictors of the adverse outcomes of COVID-19 in patients with HIV at the stage of secondary diseases to develop a predictive model of outcomes. This will help simplify the decision-making on the management of patients with COVID-19 and HIV infection at advanced stages. MATERIALS AND METHODS: This single-center study included 300 patients aged 18 years with HIV infection at advanced disease stage and moderate-to-severe COVID-19 requiring in-patient treatment. RESULTS: The mortality rate was 27.3% (95% CI, 22.7%32.4%). Factors reflecting respiratory failure, immunodeficiency, decreased levels of protein and albumin, and increased levels of urea became unfavorable. A predictive model of adverse outcomes of COVID-19 in patients with advanced HIV infection has been obtained. CONCLUSIONS: The proposed predictive model can help a practical healthcare doctor make a quick, informed decision on hospitalization of a patient in the intensive care unit and active therapeutic actions.
- 13 December 2022
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 27 (3) , 148-163
Open AccessPredictive model of COVID-19 outcomes in patients with advanced HIV infection
BACKGROUND: No studies have examined the course and outcomes of coronavirus disease 2019 (COVID-19) in patients with advanced HIV infection, which prompted this analysis. AIM: To identify predictors of the adverse outcomes of COVID-19 in patients with HIV at the stage of secondary diseases to develop a predictive model of outcomes. This will help simplify the decision-making on the management of patients with COVID-19 and HIV infection at advanced stages. MATERIALS AND METHODS: This single-center study included 300 patients aged 18 years with HIV infection at advanced disease stage and moderate-to-severe COVID-19 requiring in-patient treatment. RESULTS: The mortality rate was 27.3% (95% CI, 22.7%32.4%). Factors reflecting respiratory failure, immunodeficiency, decreased levels of protein and albumin, and increased levels of urea became unfavorable. A predictive model of adverse outcomes of COVID-19 in patients with advanced HIV infection has been obtained. CONCLUSIONS: The proposed predictive model can help a practical healthcare doctor make a quick, informed decision on hospitalization of a patient in the intensive care unit and active therapeutic actions.
- Open Access
- 7 May 2021
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (2) , 200-205
Treatment of Resistant Hypertension in Real Clinical Settings
Background. Current guidelines describe in detail the approaches to the management of patients with resistant hypertension, however, in real clinical settings the number of non-rational and ineffective combinations of antihypertensive drugs used remains high.Aim. To analyze the distribution of different combinations of antihypertensive drugs for the treatment of resistant hypertension and to estimate the proportion of non-rational combinations.Methods. The retrospective analysis includes 117 outpatients with resistant hypertension. Resistant hypertension was defined as blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes. Exclusion criteria was secondary hypertension. We defined rational combination as the standard combination (renin-angiotensin system [RAS] blocker + calcium-channel blocker [CCB] + diuretic) plus one of the group of reserve drugs (mineralocorticoid receptors antagonist [MRA], beta-blocker, alpha-blocker, agonist of imidazoline receptors [AIR]). Non-rational were considered combinations in which reserve drugs were used before the appointment of a triple combination of first-line drugs. Moreover, in a subgroup of non-rational therapy, situations were identified where such a combination was justified.Results. The proportion of rational combinations was 58.9%, reasonably non-rational - 15.5%, unreasonably non-rational - 25.6%. Unreasonably non-rational combinations are distributed as follows: non-appointment of CCB - 12%, non-appointment of RAS-blockers - 8%, non-appointment of diuretics - 6%, use of RAS-blockers for hyperkalemia - 6%, administration of MRA without non-potassium-sparing diuretics - 5%, double blockade of RAS - 3%, other combinations - 7%. In addition to first-line drugs, beta-blockers (93.2%), loop diuretics (22.2%), AIR (21.4) were the most prescribable, while the proportion of MRA is only 15.4% of the entire sample.Limitation: some patient's characteristics could be missed in case histories and some of the combinations could be falsely recognized as malpractice since the analysis was conducted retrospectively.Conclusion. The proportion of the non-rational combinations for the treatment of resistant hypertension is high. Among the drugs of the reserve, the frequent use of beta-blockers and moxonidine and the inadequate administration of spironolactone are noteworthy. The problem of treatment strategy choice remains relevant in real clinical practice.
- 7 May 2021
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (2) , 200-205
Open AccessTreatment of Resistant Hypertension in Real Clinical Settings
Background. Current guidelines describe in detail the approaches to the management of patients with resistant hypertension, however, in real clinical settings the number of non-rational and ineffective combinations of antihypertensive drugs used remains high.Aim. To analyze the distribution of different combinations of antihypertensive drugs for the treatment of resistant hypertension and to estimate the proportion of non-rational combinations.Methods. The retrospective analysis includes 117 outpatients with resistant hypertension. Resistant hypertension was defined as blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes. Exclusion criteria was secondary hypertension. We defined rational combination as the standard combination (renin-angiotensin system [RAS] blocker + calcium-channel blocker [CCB] + diuretic) plus one of the group of reserve drugs (mineralocorticoid receptors antagonist [MRA], beta-blocker, alpha-blocker, agonist of imidazoline receptors [AIR]). Non-rational were considered combinations in which reserve drugs were used before the appointment of a triple combination of first-line drugs. Moreover, in a subgroup of non-rational therapy, situations were identified where such a combination was justified.Results. The proportion of rational combinations was 58.9%, reasonably non-rational - 15.5%, unreasonably non-rational - 25.6%. Unreasonably non-rational combinations are distributed as follows: non-appointment of CCB - 12%, non-appointment of RAS-blockers - 8%, non-appointment of diuretics - 6%, use of RAS-blockers for hyperkalemia - 6%, administration of MRA without non-potassium-sparing diuretics - 5%, double blockade of RAS - 3%, other combinations - 7%. In addition to first-line drugs, beta-blockers (93.2%), loop diuretics (22.2%), AIR (21.4) were the most prescribable, while the proportion of MRA is only 15.4% of the entire sample.Limitation: some patient's characteristics could be missed in case histories and some of the combinations could be falsely recognized as malpractice since the analysis was conducted retrospectively.Conclusion. The proportion of the non-rational combinations for the treatment of resistant hypertension is high. Among the drugs of the reserve, the frequent use of beta-blockers and moxonidine and the inadequate administration of spironolactone are noteworthy. The problem of treatment strategy choice remains relevant in real clinical practice.